NCT00957398

Brief Summary

The hypothesis of the study is that the motility of the small intestine and the colon will alter according to the subtype of the irritable bowel syndrome (IBS) patient. IBS is currently classified into following subtypes:

  • Diarrhoea-IBS (IBS-D)
  • Constipation-IBS (IBS-C)
  • Mixed-IBS (IBS-M)
  • Unsubtyped-IBS (IBS-U) according to the Bristol scale. Magnetic Tracking System (MTS) is a new minimal invasive technic that allows motility studies of the whole human gastrointestinal tract. The magnetic cylindrical pill (6x15mm) is swallowed at 9 AM on day one. The recording is made until 4 PM and again from 8 AM until 2 PM on day two. The patient is placed in a bed and will be supplied with standardized food and fluid. The Magnetic Tracking System consists of a 4 x 4 matrix of sensors positioned with respect to the anatomical reference points. Before measurements, the matrix is calibrated by offsetting the earth's and environmental magnetic fields. During the experiment, the magnet coordinates are continuously monitored and transmitted to a computer for processing and storage. Respiratory artifacts will be filtered out. Digestive movements will then be classified as 1) non-propulsive or 2) propulsive and transformed into either trajectory or dynamic graphs of the digestive motility. The Magnetic Tracking System has the advantage from both radiographic and scintigraphic methods of conducting the tests without any radiation exposure to the patient. Preliminary studies have shown good concordance between the transit measured with the magnet and radiographic transit times. The investigators wish to use this method, MTS, to compare the motility of the small intestine and the colon in patients with IBS-D and IBS-C as well as to compare these to groups to MTS done on healthy volunteers under the same conditions as the IBS patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2009

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

August 11, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 12, 2009

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

May 10, 2012

Status Verified

May 1, 2012

Enrollment Period

2.7 years

First QC Date

August 11, 2009

Last Update Submit

May 9, 2012

Conditions

Keywords

Irritable Bowel SyndromeIrritable Bowel Syndrome subgroupsMotility

Study Arms (2)

IBS-D

12 IBS-D patients who will all undergo MTS.

IBS-C

12 IBS-C patients who will all undergo MTS.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

12 patients with IBS-D and 12 patients with IBS-C who all meet the inclusion criteria.

You may qualify if:

  • Patients aged over 18.
  • Patients who are diagnosed with IBS according to the Rome III criteria.
  • A total symptom score in GSRS-IBS at a minimum of 40 points.
  • Patients who are psychologically stable and suitable for observation and able to provide informed consent.

You may not qualify if:

  • Overt bowel diseases including inflammatory bowel disease.
  • Pregnant or breast feeding.
  • Patients who are considered unable to follow the planned programme of the study, including mental illness or physiological instability.
  • Patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Analfysiologisk Klinik, University of Aarhus

Aarhus, Denmark

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Janne Fassov, PhDstudent

    Analfysiologisk Klinik, University Hospital of Aarhus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD student

Study Record Dates

First Submitted

August 11, 2009

First Posted

August 12, 2009

Study Start

August 1, 2009

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

May 10, 2012

Record last verified: 2012-05

Locations